Mark J. Levin
Net Worth
Last updated:
What is Mark J. Levin net worth?
The estimated net worth of Mr. Mark J. Levin is at least $38,655,715 as of 22 Jul 2019. He owns shares worth $38,217,715 as insider and has received compensation worth at least $438,000 in Fulcrum Therapeutics, Inc..
What is the salary of Mark J. Levin?
Mr. Mark J. Levin salary is $73,000 per year as Executive Chairman in Fulcrum Therapeutics, Inc..
How old is Mark J. Levin?
Mr. Mark J. Levin is 75 years old, born in 1950.
What stocks does Mark J. Levin currently own?
As insider, Mr. Mark J. Levin owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | Executive Chairman | 5,962,202 | $6.41 | $38,217,715 |
What does Fulcrum Therapeutics, Inc. do?
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Mark J. Levin insider trading
Fulcrum Therapeutics key executives
Fulcrum Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Mr. Bryan E. Stuart (49) Pres, Chief Executive Officer & Director
- Mr. Curtis G. Oltmans J.D. (62) Senior Vice President, Gen. Counsel & Corporation Sec.
- Mr. Mark J. Levin (75) Executive Chairman